NCCN Guidelines Now Recommend Pemivibart for COVID-19 Prevention in B-Cell Lymphomas
Updated NCCN Guidelines recommend pemivibart in immunocompromised patients with B-cell lymphomas who are at higher risk of contracting COVID-19.
Related Articles
Lung Cancer Experts Highlight the Most Anticipated Abstracts at the 2025 ASCO Annual Meeting
Ahead of the 2025 ASCO Annual Meeting, lung cancer experts highlight the abstracts and related trials they’re looking forward to seeing at the meeting.
Hematology Experts Outline the Top Abstracts to Watch at the 2025 ASCO Annual Meeting
Oncology experts detail their most highly-anticipated hematology abstracts and data to watch at the upcoming 2025 ASCO Annual Meeting.
FDA Lifts Clinical Hold on Tabelecleucel Trial for EBV+ Post-Transplant Lymphoproliferative Disease
FDA lifts clinical hold on tabelecleucel IND, enabling trial resumption in EBV+ PTLD following HSCT or SOT in relapsed/refractory patients.
Breast Cancer Experts Bookmark Top Abstracts to Watch at the 2025 ASCO Annual Meeting
To prepare for the 2025 ASCO Annual Meeting, breast cancer experts share the abstracts and discussions they’re most excited to see at the meeting.
Contrasting Adjuvant and Perioperative Trial Designs Help Refine MIBC Management
Petros Grivas, MD, PhD, discusses data from CheckMate 274 and how emerging data from bladder cancer trials are shaping immunotherapy strategies in MIBC.
Signatera MRD Assay Displays High Sensitivity, Specificity in Sarcoma
The Signatera MRD assay was associated with high levels of sensitivity and specificity in sarcomas.
Updated NCCN Guidelines Recommend Naxitamab in High-Risk Neuroblastoma
The NCCN guidelines now recommend a naxitamab-based regimen for high-risk neuroblastoma.
Dr Arbour on the Role of Zoldonrasib in KRAS G12D–Mutant NSCLC
Kathryn C. Arbour, MD, highlights the safety and early efficacy of zoldonrasib in patients with non–small cell lung cancer harboring KRAS G12D mutations.
OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Exploring the Treatment Options for RRMM
Panelists discuss how treatment selection for relapsed/refractory multiple myeloma hinges on the pace of disease progression, with options ranging from second autologous transplants to chimeric…